Jakarta exchange. Sector: Healthcare. Industry: Drug Manufacturers—Specialty & Generic. Location Indonesia, Jakarta.

PT Darya-Varia Laboratoria Tbk [DVLA.JKIndonesia

2,520USD20 (+0.79%)

• At close Fri Oct 07 2022

182,968,877 USD
MARKET CAP
14.156
PE
0.028
BETA (5y)
170.952
EPS

profit

41%

for 5 years

profit

23%

for 3 years

profit

15%

for 2 years

profit

9%

for 1 year

profit

-13%

for this year

About PT Darya-Varia Laboratoria Tbk

PT Darya-Varia Laboratoria Tbk engages in the manufacture and trading of pharmaceutical products and cosmetics in Indonesia. It operates in three segments: Prescription Drugs, Consumer Health Products, and Export and Toll Manufacturing Services. It provides various prescription and consumer health products in antibiotic, antiparasit, antiseptic, anti-fungal, cough and cold, cardiology, central nervous system, gastro-hepatology, somatic, vitamin and food supplement, women healthcare, ear healthcare, and derma medic areas. The company also exports its products to Malaysia, Myanmar, the Philippines, Singapore, Vietnam, and Mongolia. The company was founded in 1976 and is headquartered in Jakarta, Indonesia. PT Darya-Varia Laboratoria Tbk is a subsidiary of Blue Sphere Singapore Pte. Ltd.

We are a long-established pharmaceutical company, committed in building a healthier Indonesia through market leading products services.

PT Darya-Varia Laboratoria Tbk
https://www.darya-varia.com
© 2022 avazzy.com. All rights reserved
Make with 🤎 and ☕ for you!

Investing involves risk, including possible loss of principal.

The strategies discussed are strictly for illustrative and educational purposes and are not a recommendation, offer or solicitation to buy or sell any securities or to adopt any investment strategy. There is no guarantee that any strategies discussed will be effective.

International investing involves risks, including risks related to foreign currency, limited liquidity, less government regulation and the possibility of substantial volatility due to adverse political, economic or other developments. These risks often are heightened for investments in emerging/ developing markets or in concentrations of single countries.